Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484101 | 1.00 | KMT2A (0.51) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL29609016 | 0.90 | PIN1 (0.60) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL14143104 | 0.90 | PIN1 (0.60) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL1153666 | 0.90 | PIN1 (0.60) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| Hydrochloric Acid SCHEMBL27856372 | 0.89 | PIN1 (0.58) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL651410 | 0.87 | HTT (0.51) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL2115724 | 0.83 | ALDH1A1 (0.51) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL2529183 | 0.82 | LMNA (0.46) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL31262315 | 0.81 | HTT (0.49) | KMT2AMEN1TAS1R3TAS1R1PIN1 | |
| SCHEMBL2448483 | 0.81 | HTT (0.49) | KMT2AMEN1TAS1R3TAS1R1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3161475-A | — | — | None | — | — | JP | disclosed |
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-114539340-B | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-116546990-A | CD73 inhibitor and pharmaceutical application thereof | 润佳（苏州）医药科技有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | disclosed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | disclosed |
| WO-2019196803-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2019-10-17 | — | — | WO | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| JP-H03161475-A | PRODUCTION OF TETRAHYDRONAPHTHALENE DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1991-07-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | KMT2A 1403/4885MEN1 709/4885TAS1R3 1692/4885 |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | KMT2A 1957/4885MEN1 3320/4885TAS1R3 2519/4885 |
| US-20230295213-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | KMT2A 2779/4885MEN1 1633/4885TAS1R3 3930/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | KMT2A 2779/4885MEN1 1633/4885TAS1R3 3930/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | KMT2A 1385/4885MEN1 696/4885TAS1R3 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.